Table 4.
Hematological toxicities attributed to treatment with bortezomib, carboplatin and etoposide administered every 21 days
| Cohort | Bortezomiba (mg m−2 dose−1) | Carboplatin AUC (day 1) | Etoposide (mg m−2 dose−1; days 1, 2, 3) | No. of patients (courses) | Neutropenia (# of courses) |
Thrombocytopenia (# of courses) |
Anemia (# of courses) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1–2 | Grade 3 | Grade 4 | Grade 1–2 | Grade 3 | Grade 4 | Grade 1–2 | Grade 3 | Grade 4 | |||||
| −1 | 0.75 | AUC 4 | 75 | 6 (14) | 5 | 2 | - | 3 | - | - | 4 | - | - |
| 1 | 1 | AUC 5 | 100 | 3 (8) | 2 | 4 | 3 | 7 | 1 | 1 | 4 | - | - |
| 1a | 0.75 | AUC 5 | 75 | 7 (22) | 4 | 10 | 2 | 14 | 3 | - | 12 | 4 | - |
| 1b | 1 | AUC 5 | 75 | 5 (15) | 4 | 2 | 5 | 6 | 2 | - | 7 | 1 | 1 |
| 2 | 1 | AUC 5 | 100 | 3 (5) | - | - | 4 | 1 | 2 | - | 1 | 2 | - |
| Total | 24 (64) | (15) | (18) | (14) | (31) | (8) | (1) | (28) | (7) | (1) | |||
Toxicity assessed according to the National Cancer Institute Common Toxicity Criteria, version 2.0
a
Bortezomib dosed on days 1, 4, 8, and 11 in dose level 1, −1, and 1a, and on days 1 and 8 in dose level 1b and 2